| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ITCH_0010600 | Exon-Exon | chr20:33001548-33057925 | chr20:34413742-34470120 | 1160 nt | 0.4509 |
| hsa_ITCH_0009400 | Exon-Exon | chr20:33001548-33069011 | chr20:34413742-34481206 | 1879 nt | 0.4343 |
| hsa_ITCH_0009500 | Exon-Exon | chr20:33001548-33080402 | chr20:34413742-34492597 | 2202 nt | 0.4301 |
| hsa_ITCH_0013100 | Exon-Exon | chr20:33012286-33026436 | chr20:34424480-34438631 | 204 nt | 0.4804 |
| hsa_ITCH_0013200 | Exon-Exon | chr20:33012286-33030108 | chr20:34424480-34442303 | 490 nt | 0.4735 |
| hsa_ITCH_0016000 | Exon-Exon | chr20:33026279-33028149 | chr20:34438474-34440344 | 348 nt | 0.4713 |
| hsa_ITCH_0016100 | Exon-Exon | chr20:33026279-33037285 | chr20:34438474-34449480 | 689 nt | 0.4659 |
| hsa_ITCH_0016200 | Exon-Exon | chr20:33026279-33059320 | chr20:34438474-34471515 | 1048 nt | 0.4532 |
| hsa_ITCH_0016300 | Exon-Exon | chr20:33026279-33080402 | chr20:34438474-34492597 | 1895 nt | 0.4232 |
| hsa_ITCH_0017400 | Exon-Exon | chr20:33027960-33028149 | chr20:34440155-34440344 | 190 nt | 0.4579 |
A review consolidating research in humans and model organisms indicates that the circITCH functions as a tumor suppressor in glioma by sponging miR-214 to allow expression of ubiquitin-protein ligase E3, thereby suppressing proliferation and preventing apoptosis, while also targeting the Wnt/β-catenin pathway [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In oesophageal squamous cell carcinoma, the circITCH is downregulated and increases ITCH expression to inhibit the Wnt/β-catenin pathway [Lee et al. DOI:10.1016/j.biopha.2018.12.052]. circITCH hsa_circ_0001141 (circITCH) was found to be lower in the hearts of cancer patients suffering from doxorubicin-induced cardiomyopathy compared to those with dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy donors, and its expression ameliorates doxorubicin-induced cardiomyocyte injury [Tian et al. DOI:10.3390/molecules26041155].